Drug Index


Mechanism :

Vigabatrin is an irreversible inhibitor of gamma- aminobutyric acid transaminase (GABA-T), the enzyme responsible for the catabolism of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. The mechanism of action of vigabatrin is attributed to irreversible enzyme inhibition of GABA-T, and consequent increased levels of the inhibitory neurotransmitter, GABA.

Indication :

  • Infantile spasm
  • Partial seizures with secondary GTC as adjunct if not controlled by other antiepileptic combination

Contraindications :

Contraindicated in pregnancy and lactation and in patients with a known hypersensitivity to vigabatrin or to any components of the product. Can exacerbate myoclonic and absence seizures. Caution in psychosis or behavioural problems. Cautionary use in children with pre-existing visual field defects. Formal assessment of visual fields (perimetry) should be undertaken in all children with a cognitive age of 9 years and above before the drug is started and every 6 months while receiving the drug. Reduce dose in renal failure.

Dosing :

Resistant partial epilepsy with or without secondary generalisation:
As an adjunct; Initially, 30-40 mg/kg daily, followed by the following maintenance dose:
10-15 kg: 0.5-1 g/day.
15-30 kg: 1-1.5 g/day.
30-50 kg: 1.5-3 g/day.
>50 kg: 2-3 g/day.
Doses to be administered once or twice daily.
Infantile spasms:
In children as monotherapy: 50 mg/kg daily, adjust according to response over 7 days. Maximum dose: 150 mg/kg daily in 1-2 divided doses.

Adverse Effect :

Dose dependent side-effects include somnolence, dizziness, headache, nervousness, depression, memory disturbances, hyperactivity, diplopia, aggression, irritability, hypo- or hypertonia. Chronic adverse effects include increased appetite and weight gain, peripheral constriction of visual fields.

Interaction :

May gradually reduce plasma phenytoin levels.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Give 50% of normal dose and titrate to response
10-20Give 50% of normal dose and titrate to response
<10Give 25% of normal dose and titrate to response

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as for GFR<10 mL/min
HDDialysed. Dose as for GFR<10 mL/min
HDF/High fluxDialysed. Dose as for GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as for GFR=10–20 mL/min

Hepatic Dose :

No dose adjustment recommended.
02/22/2024 18:02:48 Vigabatrin
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0